{"product_id":"bmrn-swot-analysis","title":"(BMRN) BioMarin Pharmaceutical Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Research Trail Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis BioMarin Pharmaceutical Inc. SWOT Analysis gives a concise view of the company’s strengths, weaknesses, opportunities, and threats to support research, investing, or strategy work; the page already includes a real preview\/sample of the analysis so you can judge style and substance before buying—purchase the full version to download the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e7 marketed rare-disease therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. has 7 marketed rare-disease therapies—Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, and Aldurazyme—which spreads sales across several ultra-rare conditions. In FY2024, total revenue was about $2.7 billion, led by Voxzogo and Vimizim, showing how this mix supports durable cash flow and a strong position in specialty metabolic and genetic disease markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e6 treatment areas served\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. serves 6 treatment areas, including MPS IV A, MPS VI, PKU, CLN2, achondroplasia, and alpha-L-iduronidase deficiency. That spread reduces dependence on one indication and supports steadier demand across rare-disease markets. It also reinforces BioMarin’s depth in enzyme replacement and genetic therapies, where it has built its pipeline and commercial scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3 pipeline assets in development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. has 3 pipeline assets in development, led by valoctocogene roxaparvovec in Phase III, plus BMN 307 and BMN 255 in Phase 1\/2. That multi-asset base gives BioMarin Pharmaceutical Inc. more shots at growth beyond current products. It also shows steady investment in high-value rare disease innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal reach across 4 regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc.’s global reach across the United States, Europe, Latin America, and other markets helps spread revenue risk and widens access for rare-disease patients. In FY2024, BioMarin reported about $2.4 billion in total revenue, showing how a multi-region base can support scale across different healthcare systems.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S., Europe, Latin America coverage\u003c\/li\u003e\n\u003cli\u003eDiversifies commercial exposure\u003c\/li\u003e\n\u003cli\u003eImproves rare-disease access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e1996-founded rare-disease specialist\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFounded in 1996, BioMarin Pharmaceutical Inc. brings 29 years of orphan-drug focus, with a 2025 base of 8 approved therapies and San Rafael, California headquarters tied to a long biotech cluster. That narrow model has built deep know-how in rare, hard-to-treat disorders and supports steady commercialization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1996-founded rare-disease specialist\u003c\/li\u003e\n\u003cli\u003e29 years of operating history\u003c\/li\u003e\n\u003cli\u003e8 approved therapies in 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioMarin’s Rare-Disease Franchise Delivers Scale and Diversified Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. stands out for its 7 marketed rare-disease therapies, spanning 6 treatment areas and reducing reliance on any one product or indication. Its FY2024 revenue of about $2.7 billion, led by Voxzogo and Vimizim, shows strong commercial scale in ultra-rare diseases. A 3-asset pipeline adds growth optionality beyond today’s portfolio.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed therapies\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTreatment areas\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$2.7 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing BioMarin Pharmaceutical Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick BioMarin SWOT snapshot to simplify strategy decisions and save time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography linking each BioMarin claim to primary industry reports, filings, and datasets to speed due diligence and boost model credibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh dependence on niche indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. still depends on niche rare-disease markets: its 2024 revenue was $2.84 billion, but each product serves a small, highly screened patient pool. That caps the addressable market and leaves growth tied to faster diagnosis, payer access, and premium pricing. If uptake slows in any one indication, the impact on revenue can be outsized.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial concentration risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. remains exposed because most 2025 revenue still came from a small rare-disease portfolio, led by Voxzogo and a few enzyme therapies. That means any safety issue, payer pressure, or slower uptake in one major product can quickly hit sales momentum. In a concentrated mix, one stumble can move the whole top line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLate-stage pipeline execution risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. still depends on a thin late-stage pipeline: valoctocogene roxaparvovec is in Phase III, while BMN 307 and BMN 255 are only in Phase 1\/2. That leaves just 1 Phase III asset versus 2 early-stage programs, so clinical, CMC, and regulatory setbacks could hit revenue replacement. Any delay can widen the gap as legacy products mature.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eComplex treatment delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc.’s weakness is the complexity of delivery: key therapies such as enzyme replacements and injectable drugs need infusion-center, hospital, or specialty-pharmacy support, which can slow starts and hurt adherence. In 2025, this still mattered because the company depends on treatments that often require repeated administration rather than simple oral dosing. That raises costs and adds friction for patients and providers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized administration limits uptake.\u003c\/li\u003e\n\u003cli\u003eAdherence drops when treatment is burdensome.\u003c\/li\u003e\n\u003cli\u003eHospitals and specialty pharmacies face strain.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExposure to reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. faces reimbursement pressure because its orphan drugs carry premium prices and depend on payer approval. Specialty and rare-disease therapies are closely reviewed by governments and insurers, so access can be delayed or narrowed even when patients need them. That risk matters most for products like Voxzogo, Brineura, and Roctavian, where coverage decisions can shape uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh prices trigger payer scrutiny.\u003c\/li\u003e\n\u003cli\u003eCoverage limits can slow access.\u003c\/li\u003e\n\u003cli\u003eRare-disease value is hard to defend.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioMarin’s Growth Risk: Concentration, Thin Pipeline, and Delivery Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. remains highly exposed to concentration risk: 2025 sales still leaned on a few rare-disease drugs, so one payer or safety setback can hit growth fast. Its pipeline is still thin, with just 1 Phase III asset versus 2 early-stage programs, so near-term revenue replacement is limited. Complex infusion and specialty-pharmacy delivery also slows starts and can hurt adherence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue mix\u003c\/td\u003e\n\u003ctd\u003e2025 still concentrated in a few products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline depth\u003c\/td\u003e\n\u003ctd\u003e1 Phase III; 2 Phase 1\/2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery burden\u003c\/td\u003e\n\u003ctd\u003eInfusion\/specialty care needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eBioMarin Pharmaceutical Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is a real excerpt from the complete BioMarin Pharmaceutical Inc. SWOT analysis you'll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report; buy now to unlock the full, editable version with detailed strengths, weaknesses, opportunities, and threats tailored for strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III gene therapy upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValoctocogene roxaparvovec targets severe hemophilia A, a rare-disease market with about 16,000 to 20,000 patients in the U.S. and Europe. If long-term efficacy holds, BioMarin could add a high-value, one-time therapy stream and widen its addressable revenue pool beyond chronic factor replacement.\u003c\/p\u003e\n\u003cp\u003eThat would also strengthen its position in durable treatment models, where one infusion can replace years of ongoing care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePKU expansion potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBMN 307 could widen BioMarin Pharmaceutical Inc.'s PKU reach by aiming to normalize blood phenylalanine, the key disease marker. PKU is already a core BioMarin area through Kuvan and Palynziq, and BioMarin reported 2025 net product revenues of about $2.4 billion, giving it an established base to sell deeper into the same rare-disease segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrimary hyperoxaluria entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBMN 255 gives BioMarin Pharmaceutical Inc. a shot at primary hyperoxaluria, a very rare disorder seen in roughly 1 to 3 people per million. That would move BioMarin beyond its core enzyme and genetic-disease lineup and into another high-unmet-need metabolic market. With BioMarin Pharmaceutical Inc. 2024 revenue at about $2.4 billion, even one new orphan win could lift diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational market growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. still has room to grow outside the United States, Europe, and Latin America, especially in countries where rare-disease diagnosis and reimbursement are still maturing. In FY2025, BioMarin generated about $2.8 billion in revenue, so even small gains in patient reach and access can move sales meaningfully. Better access programs, local payer deals, and hospital partnerships can expand treatment use for its 7 approved medicines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand access where diagnosis is still low.\u003c\/li\u003e\n\u003cli\u003eUse partnerships to speed reimbursement.\u003c\/li\u003e\n\u003cli\u003eLift reach beyond core US and Europe markets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLifecycle and label expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc.'s best upside here is lifecycle extension: Voxzogo is already approved for children 0 to 5 years with achondroplasia, while Palynziq and Vimizim can keep gaining value if used earlier or in broader patient groups. In rare disease, even a small label move can lift long-term sales because treatment is often chronic.\u003c\/p\u003e\n\u003cp\u003eThat matters against BioMarin Pharmaceutical Inc.'s 2025 revenue base of $2.4 billion, where each extra year of use can add meaningful cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVoxzogo: broader pediatric use\u003c\/li\u003e\n\u003cli\u003ePalynziq: earlier PKU treatment\u003c\/li\u003e\n\u003cli\u003eVimizim: longer patient lifetime value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioMarin’s Next Growth Driver: Earlier Labels, Bigger Rare-Disease Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. can still grow by expanding Voxzogo, Palynziq, and Vimizim into earlier use and wider patient groups. BMN 307 and BMN 255 also add pipeline shots in phenylketonuria and primary hyperoxaluria, both high-unmet-need rare diseases. BioMarin Pharmaceutical Inc. reported about $2.8 billion in FY2025 revenue, so even small access gains can move sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 revenue base\u003c\/td\u003e\n\u003ctd\u003eAbout $2.8 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePKU market\u003c\/td\u003e\n\u003ctd\u003eCore area; BMN 307 expands reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary hyperoxaluria\u003c\/td\u003e\n\u003ctd\u003e1 to 3 per million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare-disease upside\u003c\/td\u003e\n\u003ctd\u003eEarlier labels can lift lifetime value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial failure risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. still relies on late-stage and early-stage programs, so a miss in Phase III or Phase 1\/2 can hit the stock fast. Rare-disease trials are often small and hard to run, which raises the odds of noisy data and delays. In 2024, BioMarin reported about $2.4 billion in revenue, so any negative readout could quickly pressure growth expectations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory approval uncertainty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. faces high regulatory risk because gene therapies and biologics get tough FDA review, including 5–15 years of follow-up for safety and durability. Manufacturing consistency and immune-safety data can slow approval or block label expansion. For products like Roctavian, even small gaps in long-term efficacy data can delay revenue and raise trial costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and pricing resistance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. faces payer pushback because orphan drugs often cost more than $100,000 per patient a year, and insurers, pharmacy benefit managers, and governments keep tightening prior authorization and rebate demands. That can slow access even for therapies with clear clinical value, which hurts uptake and pushes out launches. In rare disease, price is often the first barrier, not the last.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCompetition in rare diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin faces intense competition in rare diseases from specialty pharma and biotech peers in genetic and metabolic disorders. As more gene and enzyme therapies reach market, rival products can pressure pricing, erode share, and shift physician choice away from BioMarin’s brands.\u003c\/p\u003e\n\u003cp\u003eRare disease momentum is rising: the FDA cleared 16 gene therapies by 2025, and the global rare disease market is already in the tens of billions of dollars, making launch speed and clinical differentiation critical.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore rivals, lower pricing power\u003c\/li\u003e\n\u003cli\u003ePhysician preference can shift fast\u003c\/li\u003e\n\u003cli\u003eGene and enzyme launches add pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing and supply complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. faces heavy manufacturing risk because its portfolio spans biologics, enzyme therapies, and gene therapy candidates, all of which need tight quality control and specialized facilities. In 2024, the Company reported $2.42 billion in revenue, so even a short supply break can hit patient access and sales fast. Gene therapy batches are especially hard to replace once delayed or rejected.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiologics need strict, costly production control.\u003c\/li\u003e\n\u003cli\u003eSupply shocks can delay patient treatment.\u003c\/li\u003e\n\u003cli\u003eAny lapse can cut BioMarin Pharmaceutical Inc. revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioMarin Faces Clinical, Payer, and Supply Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioMarin Pharmaceutical Inc. still faces patent, trial, and payer risk: one late-stage miss can reset growth, and rare-disease trials are small enough that noisy data can skew readouts. Competition from gene and enzyme therapy peers can also squeeze pricing and share. Manufacturing or FDA delays can hit supply and revenue fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical failure\u003c\/td\u003e\n\u003ctd\u003ePhase III or Phase 1\/2 miss\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer pressure\u003c\/td\u003e\n\u003ctd\u003eSlower access, lower net price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing risk\u003c\/td\u003e\n\u003ctd\u003eSupply breaks hit sales fast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234093900041,"sku":"bmrn-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bmrn-swot-analysis.webp?v=1785713341","url":"https:\/\/dcfanalyst.com\/products\/bmrn-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}